Global Lomitapide Pregnancy Exposure Registry
Global Lomitapide Pregnancy Exposure Registry
To evaluate the outcomes of pregnancy in women treated with lomitapide.
To evaluate the outcomes of pregnancy in women treated with lomitapide at any time within 30
 days prior to first day of Last Menstrual Period (LMP) or during pregnancy. The outcomes of
 primary interest are major congenital anomalies.
Inclusion Criteria:

 -  Pregnant females exposed to lomitapide at any time within 30 days prior to first day
 of the LMP or during pregnancy.

 Exclusion Criteria:

 -  Patients who are unable or unwilling to provide written informed consent or assent are
 not eligible to participate in the PER.